Alpha Cognition Other Long-Term Assets 2020-2024 | ACOG
Alpha Cognition other long-term assets from 2020 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Alpha Cognition Annual Other Long-Term Assets (Millions of US $) |
2023 |
$ |
2022 |
$ |
2021 |
$ |
2020 |
$ |
2019 |
$ |
Alpha Cognition Quarterly Other Long-Term Assets (Millions of US $) |
2024-06-30 |
$0 |
2024-03-31 |
$0 |
2023-12-31 |
|
2023-09-30 |
|
2023-06-30 |
|
2023-03-31 |
|
2022-12-31 |
|
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
2020-03-31 |
|
2019-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|